Monopar Therapeutics (MNPR) Competitors

Monopar Therapeutics (NASDAQ:MNPR) and Phibro Animal Health (NASDAQ:PAHC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Does the MarketBeat Community believe in MNPR or PAHC?

Phibro Animal Health received 271 more outperform votes than Monopar Therapeutics when rated by MarketBeat users. However, 73.33% of users gave Monopar Therapeutics an outperform vote while only 60.11% of users gave Phibro Animal Health an outperform vote.

Company	Underperform	Outperform
Monopar Therapeutics	Outperform Votes 44 73.33%	Underperform Votes 16 26.67%
Phibro Animal Health	Outperform Votes 315 60.11%	Underperform Votes 209 39.89%

Do institutionals & insiders have more ownership in MNPR or PAHC?

1.8% of Monopar Therapeutics shares are held by institutional investors. Comparatively, 99.3% of Phibro Animal Health shares are held by institutional investors. 34.9% of Monopar Therapeutics shares are held by insiders. Comparatively, 50.1% of Phibro Animal Health shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Is MNPR or PAHC more profitable?

Phibro Animal Health has a net margin of 1.75% compared to Monopar Therapeutics' net margin of 0.00%. Phibro Animal Health's return on equity of 25.35% beat Monopar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monopar Therapeutics	N/A	-107.21%	-87.57%
Phibro Animal Health	1.75%	25.35%	6.21%

Do analysts rate MNPR or PAHC?

Monopar Therapeutics presently has a consensus target price of $43.00, suggesting a potential upside of 6.83%. Phibro Animal Health has a consensus target price of $21.00, suggesting a potential downside of 6.67%. Given Monopar Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Monopar Therapeutics is more favorable than Phibro Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monopar Therapeutics	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
Phibro Animal Health	2 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Which has preferable earnings and valuation, MNPR or PAHC?

Phibro Animal Health has higher revenue and earnings than Monopar Therapeutics. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monopar Therapeutics	N/A	N/A	-$8.40M	-$1.97	-20.43
Phibro Animal Health	$1.02B	0.90	$2.42M	$0.48	46.88

Which has more volatility & risk, MNPR or PAHC?

Monopar Therapeutics has a beta of 1.3, suggesting that its share price is 30% more volatile than the S&P 500. Comparatively, Phibro Animal Health has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500.

Does the media favor MNPR or PAHC?

In the previous week, Phibro Animal Health had 11 more articles in the media than Monopar Therapeutics. MarketBeat recorded 11 mentions for Phibro Animal Health and 0 mentions for Monopar Therapeutics. Phibro Animal Health's average media sentiment score of 0.88 beat Monopar Therapeutics' score of 0.00 indicating that Phibro Animal Health is being referred to more favorably in the news media.

Company	Overall Sentiment
Monopar Therapeutics	Neutral
Phibro Animal Health	Positive

Summary

Phibro Animal Health beats Monopar Therapeutics on 12 of the 17 factors compared between the two stocks.